logo

MGRX

Mangoceuticals·NASDAQ
--
--(--)
--
--(--)
5.70 / 10
Netural

Mangoceuticals' fundamentals are mixed: a solid Interest coverage ratio (15.5) and strong Inventory turnover (47.9) offset negative year-over-year revenue declines (-29.2%). The Net profit/Total profit ratio of 100% suggests efficient earnings conversion, yet the low Total operating revenue growth highlights operational stagnation, warranting caution despite some resilient financial metrics.

Fundamental(5.7)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-3.59
Score1/3
Weight8.58%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value-29.17
Score1/3
Weight-1.04%
1M Return-0.60%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.06%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight19.91%
1M Return8.99%
PB-ROE
Value-0.37
Score3/3
Weight28.65%
1M Return13.65%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.15%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value-29.17
Score1/3
Weight-0.90%
1M Return-0.52%
Asset-MV
Value-0.51
Score3/3
Weight31.59%
1M Return11.94%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.70%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight19.12%
1M Return8.80%
Is MGRX undervalued or overvalued?
  • MGRX scores 5.70/10 on fundamentals and holds a Fair valuation at present. Backed by its -126.42% ROE, -4245.52% net margin, -0.31 P/E ratio, 0.40 P/B ratio, and 55.99% earnings growth, these metrics solidify its Netural investment rating.